| scholarly article | Q13442814 |
| P2093 | author name string | Emily S Spivak | |
| Kimberly E Hanson | |||
| P2860 | cites work | Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal's medium | Q39092219 |
| Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis | Q39092224 | ||
| The first cases of Candida auris candidaemia in Oman | Q39092264 | ||
| The yeasticidal activity of chemical disinfectants and antiseptics against Candida auris. | Q39092268 | ||
| Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. | Q39092317 | ||
| Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation | Q39092330 | ||
| Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. | Q39092336 | ||
| Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017. | Q39092357 | ||
| Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? | Q42326663 | ||
| Candida auris-associated candidemia, South Africa | Q42712931 | ||
| Candida auris candidemia in Kuwait, 2014. | Q42787996 | ||
| Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features | Q43521723 | ||
| Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016. | Q50985111 | ||
| The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis | Q51188122 | ||
| An experimental model for study of Candida survival and transmission in human volunteers | Q72370297 | ||
| Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia | Q28818814 | ||
| Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species | Q28829671 | ||
| Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study | Q29616607 | ||
| Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts | Q30561825 | ||
| Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital | Q33401940 | ||
| Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. | Q33609053 | ||
| First three reported cases of nosocomial fungemia caused by Candida auris | Q34196357 | ||
| New clonal strain of Candida auris, Delhi, India | Q34372060 | ||
| Draft Genome Sequence of a Fluconazole-Resistant Candida auris Strain from a Candidemia Patient in India | Q34485537 | ||
| Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris | Q34492906 | ||
| First hospital outbreak of the globally emerging Candida auris in a European hospital | Q34543358 | ||
| Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses | Q34547546 | ||
| Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek | Q35586995 | ||
| Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. | Q35835357 | ||
| Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry | Q36049838 | ||
| Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies | Q36943829 | ||
| Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel | Q37664411 | ||
| Phylogeny and evolution of medical species of Candida and related taxa: a multigenic analysis | Q37702433 | ||
| Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Healthcare Surface | Q38659451 | ||
| Candida auris candidaemia in Indian ICUs: analysis of risk factors | Q38883902 | ||
| The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. | Q38949297 | ||
| Identification of Candida haemulonii Complex Species: Use of ClinProTools(TM) to Overcome Limitations of the Bruker Biotyper(TM), VITEK MS(TM) IVD, and VITEK MS(TM) RUO Databases | Q39033046 | ||
| In vitro efficacy of disinfectants utilised for skin decolonization and environmental decontamination during a hospital outbreak with Candida auris. | Q39092094 | ||
| Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. | Q39092102 | ||
| Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. | Q39092125 | ||
| Effectiveness of Disinfectants Against Candida auris and Other Candida Species | Q39092133 | ||
| First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia | Q39092138 | ||
| Incidence, characteristics and outcome of ICU-acquired candidemia in India | Q39092143 | ||
| Multidrug-resistant endemic clonal strain of Candida auris in India. | Q39092162 | ||
| Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris | Q39092215 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida auris | Q26816853 |
| P577 | publication date | 2017-11-22 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Candida auris: An Emerging Fungal Pathogen |
| Q89510130 | Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? |
| Q95642098 | Candida auris: From Multidrug Resistance to Pan-Resistant Strains |
| Q54242269 | Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. |
| Q94484082 | Cloning and heterologous expression of P450Lent4B11, a novel bacterial P450 gene, for hydroxylation of an antifungal agent sordaricin |
| Q92915825 | Draft Genome Sequence of Candida auris Strain LOM, a Human Clinical Isolate from Greater Metropolitan Houston, Texas |
| Q92082086 | Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens |
| Q114115328 | Eradication of Fungi Using MoSe2/Chitosan Nanosheets |
| Q59804393 | Filamentation in Candida auris, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch |
| Q64226654 | Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS |
| Q56993529 | Identification of Antifungal Targets Based on Computer Modeling |
| Q94465214 | Impact of a New Portable Air Purification Technology Device in the Pediatric Hospital Setting - A Pre-post Assessment Study |
| Q90573021 | In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism |
| Q104135019 | In vitro synergy of isavuconazole in combination with colistin against Candida auris |
| Q90146452 | Isolation of Candida auris from invasive and non-invasive samples of a patient suffering from vascular disease, Italy, July 2019 |
| Q89494813 | Machine Learning Approach for Candida albicans Fluconazole Resistance Detection Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry |
| Q54264698 | Misidentification of Candida auris by RapID Yeast Plus, a Commercial, Biochemical Enzyme-Based Manual Rapid Identification System. |
| Q59795951 | Molecular diagnostics in medical mycology |
| Q64359214 | New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): Focus on environmental survival and germicide susceptibility |
| Q91760598 | Reagent-Free Identification of Clinical Yeasts by Use of Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy |
| Q91899329 | Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study |
| Q53683158 | The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future. |
| Q91529794 | The Fungal Histone Acetyl Transferase Gcn5 Controls Virulence of the Human Pathogen Candida albicans through Multiple Pathways |
| Q98771335 | The Postbiotic Activity of Lactobacillus paracasei 28.4 Against Candida auris |
| Q55312173 | The first isolate of Candida auris in China: clinical and biological aspects. |
| Q92543398 | The role of Lactobacillus species in the control of Candida via biotrophic interactions |
Search more.